Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

NT-proanp and NT-probnp for the diagnosis of stroke

A kind of use, the technology of the subject, applied in the kit and device for implementing the method of the present invention, reagent and kit, diagnosing the acute cerebral ischemic event in the subject, the system field of diagnosing the acute cerebral ischemic event, can Solve the problems of non-specificity, separation of other diseases, and inability to be verified

Active Publication Date: 2014-10-08
F HOFFMANN LA ROCHE & CO AG
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As such, many symptoms may be nonspecific
Also, since they exist only temporarily, they cannot be verified
Therefore, the diagnosis of TIA can be difficult and cannot be easily separated from other disorders

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • NT-proanp and NT-probnp for the diagnosis of stroke
  • NT-proanp and NT-probnp for the diagnosis of stroke
  • NT-proanp and NT-probnp for the diagnosis of stroke

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0217] Example 1: Determination of NT-proBNP and NT-proANP

[0218] NT-proBNP was determined using Roche's electrochemiluminescence ELISA sandwich assay Elecsys proBNP II STAT (Short Turn Around Time) assay. The test employs two monoclonal antibodies that recognize epitopes located in the N-terminal portion (1-76) of pro-BNP(1-108).

[0219] NT-proANP (amino acids 1 to 98 of the pre-proANP peptide) was determined using the NT-proANP assay from Biomedica Medizinprodukte GmbH (Vienna, Austria). Catalog number BI-20892. The limit of detection is 0.05 nmol / l. This assay utilizes a polyclonal sheep antigen ANP antibody.

[0220] The levels of biomarkers were tested in the serum samples of the following subject groups.

[0221] · Healthy subjects (n=149)

[0222] · Patients with stable coronary artery disease CAD (i.e. patients in whom strokes frequently develop, n=235),

[0223] Patients with cardiac decompensation (n=64),

[0224] • Patients with TIA (n=79).

[0225] · Pat...

Embodiment 2

[0230] Example 2: Results

[0231] The following results were obtained (shown as median level, and 25 th and 75 th percentage):

[0232]

[0233]

[0234] A surprising finding indicates that NT-proANP levels in stroke are significantly increased in patients with TIA and stroke. Specifically, they were higher than in overt cardiac decompensation. Thus, NT-proANP separates heart disease patients from stroke patients. Measurement of NT-proBNP provides additional information.

[0235] Furthermore, the ratio of NT-proANP to NT-proBNP was determined:

[0236] The ratios are as follows (median, 25th percentile / 75th percentile):

[0237]

[0238] As can be seen from the table, the determination of the ratio is advantageous because it allows to compare i) patients with risk factors for stroke / TIA, i.e. patients with coronary artery disease (CAD) and patients with heart failure (HF ) with high levels of NT-proANP and NT-proBNP, and ii) patients with stroke or TIA.

[02...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for diagnosing a transitory ischemic attack (TIA) in a subject who is suspected to have exhibited a transitory ischemic attack, but who did not exhibit a stroke. The method is based on the determination of the amount of NT-proANP in a sample from said subject. Moreover, the present invention is directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the determination of the amounts of NT-proBNP and NT-proANP in a sample from a subject. The method further comprises the step of calculating a ratio of the amounts of NT-proBNP and NT-proANP. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.

Description

field of invention [0001] The present invention relates to a method for diagnosing a transient ischemic attack (TIA) in a subject who is suspected of having exhibited a transient ischemic attack (Transitory ischemic attack), but has not yet exhibited a stroke ( stroke). The method is based on the determination of the amount of NT-proANP in a sample from said subject. Furthermore, the present invention is also directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the amount of NT-proBNP and NT-proANP in a sample from the subject Determination. The method further comprises the step of calculating the ratio of the amounts of NT-proBNP and NT-proANP. The present invention also relates to systems for performing TIA diagnosis and for diagnosing acute cerebral ischemic events, and reagents and kits for use in performing the methods disclosed herein. The invention further encompasses kits and devices suitable for carrying out the methods of the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N33/74G01N2800/50G01N2800/2871G01N33/6896G01N33/6893G01N2333/58
Inventor G.赫斯A.霍希D.祖内克
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com